| Product Code: ETC4639986 | Publication Date: Nov 2023 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Canada Orphan Drugs Market Overview |
3.1 Canada Country Macro Economic Indicators |
3.2 Canada Orphan Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Canada Orphan Drugs Market - Industry Life Cycle |
3.4 Canada Orphan Drugs Market - Porter's Five Forces |
3.5 Canada Orphan Drugs Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Canada Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Canada Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2021 & 2031F |
4 Canada Orphan Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of rare diseases in Canada |
4.2.2 Supportive government regulations and policies for orphan drugs |
4.2.3 Growing focus on personalized medicine and targeted therapies |
4.3 Market Restraints |
4.3.1 High cost of orphan drugs leading to affordability issues |
4.3.2 Limited awareness and access to orphan drugs in remote areas |
4.3.3 Challenges in obtaining reimbursement for orphan drugs |
5 Canada Orphan Drugs Market Trends |
6 Canada Orphan Drugs Market Segmentations |
6.1 Canada Orphan Drugs Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Canada Orphan Drugs Market Revenues & Volume, By Revlimid, 2021-2031F |
6.1.3 Canada Orphan Drugs Market Revenues & Volume, By Rituxan, 2021-2031F |
6.1.4 Canada Orphan Drugs Market Revenues & Volume, By Opdivo, 2021-2031F |
6.1.5 Canada Orphan Drugs Market Revenues & Volume, By Keytruda, 2021-2031F |
6.1.6 Canada Orphan Drugs Market Revenues & Volume, By Imbruvica, 2021-2031F |
6.1.7 Canada Orphan Drugs Market Revenues & Volume, By Soliris, 2021-2031F |
6.2 Canada Orphan Drugs Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 Canada Orphan Drugs Market Revenues & Volume, By Biologics, 2021-2031F |
6.2.3 Canada Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2021-2031F |
6.3 Canada Orphan Drugs Market, By Therapy Class |
6.3.1 Overview and Analysis |
6.3.2 Canada Orphan Drugs Market Revenues & Volume, By Oncology, 2021-2031F |
6.3.3 Canada Orphan Drugs Market Revenues & Volume, By Blood, 2021-2031F |
6.3.4 Canada Orphan Drugs Market Revenues & Volume, By Endocrine, 2021-2031F |
6.3.5 Canada Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2021-2031F |
6.3.6 Canada Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2021-2031F |
6.3.7 Canada Orphan Drugs Market Revenues & Volume, By Respiratory, 2021-2031F |
7 Canada Orphan Drugs Market Import-Export Trade Statistics |
7.1 Canada Orphan Drugs Market Export to Major Countries |
7.2 Canada Orphan Drugs Market Imports from Major Countries |
8 Canada Orphan Drugs Market Key Performance Indicators |
8.1 Number of orphan drug designations granted by Health Canada |
8.2 Patient enrollment in clinical trials for orphan drugs |
8.3 Percentage increase in funding for rare disease research and treatment |
9 Canada Orphan Drugs Market - Opportunity Assessment |
9.1 Canada Orphan Drugs Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Canada Orphan Drugs Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 Canada Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2021 & 2031F |
10 Canada Orphan Drugs Market - Competitive Landscape |
10.1 Canada Orphan Drugs Market Revenue Share, By Companies, 2024 |
10.2 Canada Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here